Daily Stock Analysis, ABBV, AbbVie Inc, priceseries

AbbVie Inc. Daily Stock Analysis
Stock Information
Open
61.84
Close
61.81
High
62.11
Low
61.50
Previous Close
61.77
Daily Price Gain
0.04
YTD High
63.86
YTD High Date
Jan 10, 2017
YTD Low
59.27
YTD Low Date
Jan 30, 2017
YTD Price Change
0.02
YTD Gain
0.04%
52 Week High
66.82
52 Week High Date
Aug 15, 2016
52 Week Low
51.76
52 Week Low Date
Feb 22, 2016
52 Week Price Change
8.57
52 Week Gain
16.09%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 8. 2015
54.68
May 1. 2015
60.51
17 Trading Days
10.66%
Link
LONG
Oct 29. 2015
51.57
Nov 11. 2015
58.32
9 Trading Days
13.09%
Link
LONG
Apr 1. 2016
55.31
Apr 28. 2016
58.25
19 Trading Days
5.32%
Link
Company Information
Stock Symbol
ABBV
Exchange
NYSE
Company URL
http://www.abbvie.com
Company Phone
(847) 932-7900
CEO
Richard A. Gonzalez
Headquarters
Illinois
Business Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001551152
About

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the trea...

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.